{"entity":{"id":"paper-hunder-cd4-ny-eso-1-melanoma-nejm-2008","kind":"paper","name":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","aka":[],"tldr":"A case report of one person with melanoma that no treatment had controlled, who went into a lasting remission after an infusion of their own helper T cells grown against the NY-ESO-1 protein.","summary":"The authors developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones specific for the melanoma-associated antigen NY-ESO-1 and infused them into a patient with refractory metastatic melanoma who had had no prior conditioning or cytokine treatment (New England Journal of Medicine 2008). The transferred cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1 (New England Journal of Medicine 2008).","asOf":"2026-11-05","links":[{"label":"DOI 10.1056/NEJMoa0800251","url":"https://doi.org/10.1056/NEJMoa0800251"},{"label":"PubMed 18565862","url":"https://pubmed.ncbi.nlm.nih.gov/18565862/"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["ctag1b"],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"journal":"The New England Journal of Medicine","year":2008,"doi":"10.1056/NEJMoa0800251","pmid":"18565862","authors":"Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C.","paperType":"translational","findings":["Autologous NY-ESO-1-specific CD4+ T-cell clones, given without conditioning or cytokines, produced a durable clinical remission in one patient with refractory metastatic melanoma.","The patient developed endogenous responses to melanoma antigens other than NY-ESO-1."],"whatItMeans":"Helper (CD4+) T cells, not only killer (CD8+) T cells, can drive a remission, and one targeted infusion can widen the immune response to other tumour antigens.","caveats":["One patient; a case report, not a trial result."],"participants":1},"route":"/key-papers/paper-hunder-cd4-ny-eso-1-melanoma-nejm-2008/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}